» Articles » PMID: 27966058

Surgical Considerations in the Treatment of Small Bowel Crohn's Disease

Overview
Specialty Gastroenterology
Date 2016 Dec 15
PMID 27966058
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Surgery remains a cornerstone of the management of Crohn's disease (CD). Despite the rise of biologic therapy, most CD patients require surgery for penetrating, obstructing, or malignant complications. Optimal surgical therapy requires sophisticated operative judgment and medical optimization. Intraoperatively, surgeons must balance treatment of CD complications against bowel preservation and functional outcome. This demands mastery of multiple techniques for anastomosis and strictureplasty, accurate assessment of bowel integrity for margin minimization, and a comprehensive skillset for navigating adhesions and altered anatomy, controlling thickened mesentery, and safely managing the hostile abdomen. Outside of the operating room, a multi-disciplinary team is critical for pre-operative optimization, patient support, and medical management. Postoperatively, prevention and surveillance of recurrence remain a matter of research and debate, and medical options include older drugs with limited efficacy and tolerability versus biologic agents with greater effect sizes and shorter track records. The evidence base for current management is limited by the inherent challenges of studying a chronic disease marked by heterogeneity and recurrence, but also by a lack of prospective trials incorporating both medical and surgical therapies.

Citing Articles

Creeping Fat in Crohn's Disease-Surgical, Histological, and Radiological Approaches.

Aggeletopoulou I, Tsounis E, Mouzaki A, Triantos C J Pers Med. 2023; 13(7).

PMID: 37511642 PMC: 10381426. DOI: 10.3390/jpm13071029.


Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease.

Lewin S, Velayos F Gastroenterol Hepatol (N Y). 2021; 16(9):449-457.

PMID: 34035752 PMC: 8132655.


Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease.

Pellino G, Keller D, Sampietro G, Angriman I, Carvello M, Celentano V Tech Coloproctol. 2020; 24(5):421-448.

PMID: 32172396 DOI: 10.1007/s10151-020-02183-z.


Mesenteric excision surgery or conservative limited resection in Crohn's disease: study protocol for an international, multicenter, randomized controlled trial.

Li Y, Mohan H, Lan N, Wu X, Zhou W, Gong J Trials. 2020; 21(1):210.

PMID: 32085793 PMC: 7035646. DOI: 10.1186/s13063-020-4105-x.


Letter to the Editor: Mesenteric Lymphatic Vessel Density Is Associated with Disease Behavior and Postoperative Recurrence in Crohn's Disease.

Dickerson L, De Freitas S, Pozo M, Safar B J Gastrointest Surg. 2018; 23(1):181-182.

PMID: 30276589 DOI: 10.1007/s11605-018-3987-3.


References
1.
Bakkevold K . Construction of an ileocolic neosphincter - Nipple valve anastomosis for prevention of postoperative recurrence of Crohn's disease in the neoterminal ileum after ileocecal or ileocolic resection. A long-term follow-up study. J Crohns Colitis. 2010; 3(3):183-8. DOI: 10.1016/j.crohns.2009.04.002. View

2.
Canedo J, Lee S, Pinto R, Murad-Regadas S, Rosen L, Wexner S . Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates?. Colorectal Dis. 2010; 13(11):1294-8. DOI: 10.1111/j.1463-1318.2010.02469.x. View

3.
Hanauer S, Korelitz B, Rutgeerts P, Peppercorn M, Thisted R, Cohen R . Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004; 127(3):723-9. DOI: 10.1053/j.gastro.2004.06.002. View

4.
Frolkis A, Lipton D, Fiest K, Negron M, Dykeman J, DeBruyn J . Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol. 2014; 109(11):1739-48. DOI: 10.1038/ajg.2014.297. View

5.
Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E . Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol. 1996; 8(3):229-33. DOI: 10.1097/00042737-199603000-00008. View